Immuno-Oncology Webinar: Different Routes To The Same Destination
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has shot out of the starting gate in the great immuno-oncology race, with Merck & Co hot on its tail. Frenzied deal making and exponential growth in the number of investigational products and clinical trials taking place suggest, however, that there is ample room for a range of players in this market.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.